Navigation Links
IDRI Awarded Contract from BARDA to Develop Next Generation Adjuvants for Pandemic Influenza
Date:12/3/2010

SEATTLE, Dec. 4, 2010 /PRNewswire-USNewswire/ -- The Infectious Disease Research Institute (IDRI) has been awarded an $1.8 million contract from the Biomedical Advance Research and Development Authority (BARDA). IDRI's work will focus on development of adjuvant formulations with options up to $8.5 million over three years when further development and manufacture of priority candidates are approved by the agency.

"BARDA is supporting an important expansion of IDRI's technology to solutions that address Neglected Diseases as well as those that affect us all in the United States," says Dr. Darrick Carter, Director of Formulations at IDRI and Principal Investigator on the BARDA influenza contract. Adjuvants and other immunostimulants can improve the body's immune response to diseases like influenza, in turn, reducing the amount of vaccine needed for protection (dose-sparing). The use of adjuvants will allow for expansion of vaccine supply to meet the necessary global demands during a pandemic.

BARDA is within the U.S. Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response. The project is part of the innovations portfolio awarded out of BARDA's Strategic Science and Technology Division's Innovation BAA (Broad Agency Announcement).

About IDRI's Adjuvants

Adjuvants are compounds used to improve the body's immune response to vaccines. Adjuvant technology is proving invaluable in the development of vaccines for serious diseases for which vaccines are not currently available, including malaria and HIV.

Adjuvants are a key research component of IDRI's malaria, tuberculosis, leishmaniasis and leprosy vaccine development programs — supported by the Bill and Melinda Gates Foundation, the National Institutes of Health, and the American Leprosy Missions.

About IDRI – Translating science into global health solutions

IDRI is a Seattle-based not-for-profit organization committed to applying innovative science to the research and development of products to prevent, detect, and treat infectious diseases of poverty. By integrating capabilities — including preclinical vaccinology, manufacturing, and clinical trials — IDRI strives to create an efficient pathway bringing scientific innovation from the lab to the people who need it most.

For more information, go to www.idri.org  


'/>"/>
SOURCE Infectious Disease Research Institute (IDRI)
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
2. Federal Funding Awarded to Test Antimicrobial Properties of Copper Metals
3. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
4. Nobel Prize Awarded to Foundation for Biomedical Research Board Member
5. National Jewish, Brigham and Womens Awarded $37 Million to Identify Genes and Other Risk Factors that Influence the Development of COPD
6. SAIC Awarded Malaria Vaccine Production Support Contract Extension by the National Institute of Allergy and Infectious Diseases
7. Congressional Funds Awarded for Testing of Antimicrobial Copper Metals
8. DiObex, Inc. Awarded Patent for the Prevention of Insulin-Induced Hypoglycemia
9. Fundamental Applied Biology, Inc. Is Awarded SBIR Phase IIB Grant for the Commercialization of Protein Therapeutics Using Cell Free Technology
10. New Patent Awarded for Antigen-Sparing Vaccines that Elicit Robust Immunity
11. TriLink Awarded a Phase II Grant for a Second Hot Start PCR Project
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... NEW YORK , Jan. 17, 2017 ... USD 8.02 billion by 2021 from USD 6.35 billion ... major factors driving the growth of this market are ... increasing demand for minimally invasive surgeries. The ... type, procedure, application, and region. On the basis of ...
(Date:1/17/2017)... , Jan. 17, 2017  Jazz Pharmaceuticals plc (Nasdaq: ... patient has been enrolled in a Phase 3 clinical ... best supportive care (BSC) in the prevention of hepatic ... hematopoietic stem cell transplant (HSCT) who are at high ... The defibrotide clinical trial will be conducted across approximately ...
(Date:1/17/2017)... 17, 2017  Market Research Future published a Half Cooked Research ... expected to reach USD 33.6 million during the period 2016 to ... ... Devices Market has been examined as a swiftly growing market and ... demand for endoscopy device in various regions.  The increasing growth in ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... , ... SC&H Group, a leading audit, tax, and consulting firm, announced that ... Services practice . Rossi is the third technology consulting leader to join SC&H Group’s ... and the practice continues to expand.     , Bringing more than 25 years of business ...
(Date:1/17/2017)... ... January 17, 2017 , ... Physicians Education Review®, LCC ... keynote speaker for the 34th Annual Miami Breast Cancer Conference®, on March 9-12, ... president, Phil Talamo, said, “We are delighted to have Sandra Lee join us ...
(Date:1/17/2017)... ... ... make New Year’s resolutions or renew their commitment to better health with the start of ... want to kick off 2017 with better smiles. Dr. Mondavi is offering several promotions for ... , , A new patient package for just $49, which can ...
(Date:1/16/2017)... Boston, MA (PRWEB) , ... January 17, 2017 ... ... winter season, Au Bon Pain, an internationally recognized leader in the fast-casual category, ... new items such as the Good Egg Breakfast Sandwich, Turkey Mash-Up Sandwich, Cranberry ...
(Date:1/16/2017)... ... 2017 , ... Gym Source, America’s leading retailer of premium residential and commercial ... Jersey. , “We are elated to be opening this new showroom,” explains Tom Richard, ... give clients a seamless and motivating shopping experience.” , Every fitness journey is unique, ...
Breaking Medicine News(10 mins):